XOMA Corporation

XOMA Corporation operates as a biotechnology royalty aggregator, acquiring potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support in exchange for future royalties from successful drug development and commercialization.

Products

• Biotechnology royalty aggregation services